How to access Soliris from Saudi Arabia — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A Saudi patient with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), or neuromyelitis optica spectrum disorder (NMOSD) may receive a prescription for Soliris (eculizumab) from their treating haematologist, nephrologist, or neurologist. Soliris is FDA-approved in the United States and manufactured by Alexion (AstraZeneca Rare Disease). It is a humanised monoclonal antibody that inhibits terminal complement activation. Because Soliris is a complement inhibitor, access is coordinated with the manufacturer's controlled-distribution model and physician training/registration expectations; the named-patient pathway respects those parameters while solving supply and formulary gaps. In Saudi Arabia, Soliris may be available in limited tertiary settings but not broadly stocked, which is why your physician may be navigating a named-patient import pathway with you.
This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Soliris is administered as an IV infusion every two weeks after an induction period. It carries a US boxed warning regarding life-threatening meningococcal infections, which is why meningococcal vaccination (or appropriate antibiotic prophylaxis if vaccination is not feasible in time) is a gating step before therapy begins, as is enrolment in the US REMS program. Internationally, equivalent manufacturer risk-minimisation measures apply. Your treating physician confirms diagnosis, vaccination status, prior therapy history, and the monitoring plan per FDA labeling.
Is Soliris legally importable into Saudi Arabia?
Yes — through the Saudi Food and Drug Authority (SFDA) named-patient import framework. The pathway allows a Saudi-licensed physician to request import of a medicine not broadly registered locally when: (a) the medicine is approved by a recognised reference authority (FDA qualifies), (b) no locally registered alternative is clinically equivalent for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented through a licensed importing entity.
For eculizumab specifically, international access respects the manufacturer's controlled-distribution program and the physician-registration expectations tied to the meningococcal-infection risk profile.
How the pathway works, step by step
- Consultation with your treating physician. Diagnosis confirmation (flow cytometry for PNH; clinical and complement/ADAMTS13 criteria for aHUS; AChR-antibody for gMG; AQP4-IgG for NMOSD), and clinical rationale.
- Meningococcal vaccination / prophylaxis. Vaccination at least 2 weeks before first dose, or appropriate antibiotic cover per labeling.
- SFDA named-patient application. The physician or hospital pharmacy files the application.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner, aligned with the manufacturer's controlled-distribution model.
- Cold-chain shipment. Soliris ships at 2–8°C with continuous temperature monitoring.
- Arrival, induction, and maintenance dosing. The infusion facility administers on the induction-then-biweekly schedule.
What documentation your physician needs
Your physician will typically need to provide:
- Clinical rationale letter confirming indication, diagnostic evidence, prior therapies, and Soliris as the indicated treatment
- Verification of Saudi medical licence
- Patient identifier
- Meningococcal vaccination documentation or prophylaxis plan
- Planned induction and biweekly maintenance regimen
Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for complement inhibitors, including the meningococcal-infection risk-minimisation block.
Costs and timing
Soliris's US cash-pay reference price per 300 mg vial sits in a broad indicative range that makes the total course one of the most expensive therapies in global use — annualised treatment costs for PNH or aHUS are typically quoted in the USD 500,000+ range in US list pricing. International cold-chain logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.
Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 14–28 days from the moment a complete application is submitted (vaccination lead time may extend this). Maintenance doses ship on a rolling biweekly basis.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Soliris specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody and aligned with the manufacturer's controlled-distribution program.
- Documentation. Regulatory package for your physician and for SFDA review, including the meningococcal-risk-minimisation block.
- Logistics. Cold-chain, temperature-monitored shipment.
- Concierge case lead. A named point of contact.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician.
Frequently asked
Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation and respect for the manufacturer's controlled-distribution expectations.
What about the meningococcal warning? It is load-bearing. Vaccination at least 2 weeks before first dose, or antibiotic prophylaxis per labeling, is non-negotiable. Your physician coordinates this before treatment starts.
Is Ultomiris an alternative? Yes — Ultomiris (ravulizumab) is a longer-interval C5 inhibitor in the same family, dosed every eight weeks. Your physician will choose between them based on clinical profile, prior exposure, and logistics.
Will private insurance cover this? Cash-pay is the default. Some Saudi insurers reimburse named-patient imports for ultra-rare-disease therapies on escalated review; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Soliris coordination in Saudi Arabia.
Add me to the Soliris waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.